Mercury Laboratories Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L74239MH1982PLC026341 Incorporated 12 February 1982 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 538964 Public Limited Company pharma MSME · Medium
Market Cap
₹90.00 Cr
MERCURYLAB · BSE
Share Price
₹748.90
-0.15% today
Revenue
₹75.94 Cr
FY 2025-26 · +1.1% YoY
EBITDA
₹8.64 Cr
Margin 11.4%
Net Profit
₹5.14 Cr
FY 2025-26 · +67.4% YoY
P/E (TTM)
27.3x
P/B 1.6x
ROE
8.7%
ROCE 11.3%
Debt / Equity
0.12
Interest cover 10.3x

About Mercury Laboratories Limited

Data last updated:

Mercury Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 February 1982 and has been in existence for over 44 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L74239MH1982PLC026341. Its GSTIN is 27AAACM0414D2Z5 (Maharashtra). The company holds 10 GST registrations, of which 8 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 538964.

The company has an authorised share capital of ₹2.5 Cr and a paid-up capital of ₹1.2 Cr. It was formerly known as Mercury Laboratories Private Limited. It is led by directors including Rajendrakumar Ramanlal Shah (Managing Director) and Paresh Jagdishbhai Mistry.

Its last annual general meeting (AGM) was held on 13 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shreeji Mang Idas Marketprincess Street, Mumbai, Maharashtra, India – 400002.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹75.94 Cr, a growth of 1.1% compared to the previous year. For the same year it recorded a net profit of ₹5.14 Cr (net margin 6.8%) and EBITDA of ₹8.64 Cr (EBITDA margin 11.4%). The net worth stands at ₹58.08 Cr (up 8.4% YoY). Total assets are valued at ₹67.22 Cr (up 13.2% YoY).

The company has about 492 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Mercury Laboratories. As per MCA filings, the company has open charges of ₹35.71 Cr and satisfied charges of ₹33.61 Cr on record. Court records list 71 cases involving the company, including 40 filed by the company and 31 filed against it; 13 cases are pending. The company has 1 deal on record (1 market trade); the latest was in May 2023. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Asence Pharma Private Limited with revenue of ₹77.56 Cr. The company has 5 MSME Form 1 returns on record between 2019 and 2021, listing 616 overdue payments to 33 micro and small suppliers.

Mercury Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-24-0002899). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mercurylabs.com.

Company details

CIN L74239MH1982PLC026341
Registration Number 026341
Incorporation Date 12 February 1982
ROC Mumbai
Listing Status Listed - Listed on BSE (538964)
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-24-0002899

CIN history

Mercury Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74239MH1982PLC026341, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74239MH1982PLC026341Current
U74239MH1982PTC026341Previous
U74239MH1982PLC026341Previous

Recognitions & Rankings of Mercury Laboratories

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-GJ-24-0002899

Contact details

Mercury Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is mercurylabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    Shreeji Mang Idas Marketprincess Street, Mumbai, Maharashtra, India – 400002
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Mercury Laboratories Limited, buy the company report.

Comprehensive company report
Mercury Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Mercury Laboratories operates one associated brand: Mercury Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Pharmaceutical drugs are manufactured by Mercury Laboratories in India.mercurylabs.com

Business activity

The main business activity of Mercury Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Mercury Laboratories Limited, buy the company report.

Financials of Mercury Laboratories Limited

FY 2025-26 filings available

Mercury Laboratories Limited reported revenue of ₹75.94 Cr (up 1.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹75.94 Cr
+1.1% YoY
EBITDA
₹8.64 Cr
+23.1% YoY
Profit After Tax
₹5.14 Cr
+67.4% YoY
Net Worth
₹58.08 Cr
+8.4% YoY
Total Assets
₹67.22 Cr
+13.2% YoY
Total Debt
₹8.43 Cr
+54.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue75.9475.1075.5675.3357.9268.6057.27
Revenue growth+1.1%-0.6%+0.3%+30.1%-15.6%+19.8%-
EBITDA8.647.029.028.586.989.596.16
EBITDA margin+11.4%+9.4%+11.9%+11.4%+12.1%+14.0%+10.8%
Profit before tax6.644.666.917.465.027.914.32
Net profit5.143.075.595.623.445.343.22
Net profit margin+6.8%+4.1%+7.4%+7.5%+5.9%+7.8%+5.6%
EPS (₹)40.2826.2147.1246.4929.6844.4826.90
Balance sheet
Total assets67.2259.4056.7051.4647.5445.2740.36
Net worth58.0853.5750.8445.6340.3136.8931.98
Total debt8.435.455.555.835.997.107.19
Cash & bank6.182.198.237.326.934.872.51
Net working capital34.6525.8029.8528.6722.5419.8317.32
Cash flow
Cash from operations4.244.868.232.455.198.215.49
Cash from investing(3.17)(9.04)(6.27)(1.06)(1.89)(4.62)(1.14)
Cash from financing2.91(1.85)(1.04)(1.01)(1.23)(1.24)(3.33)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.0115.9620.4418.3519.0118.1420.6619.57
Revenue growth (YoY)0.0%-12.0%-1.1%-6.2%+4.5%+8.8%--
Other income0.380.050.670.310.790.180.180.53
Total expenses17.5714.7718.4016.2316.8815.7818.5417.60
EBITDA1.441.192.042.122.132.362.121.97
EBITDA margin+7.6%+7.5%+10.0%+11.6%+11.2%+13.0%+10.3%+10.1%
Depreciation0.740.730.840.870.860.840.730.74
Interest0.160.120.130.140.130.150.130.13
Profit before tax0.920.391.741.421.931.551.441.63
Tax0.240.090.510.440.280.580.340.45

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.0115.9620.4418.3519.0118.1420.6619.57
Revenue growth (YoY)0.0%-12.0%-1.1%-6.2%+4.5%+8.8%--
Other income0.380.050.670.310.790.180.180.53
Total expenses17.5714.7718.4016.2316.8815.7818.5417.60
EBITDA1.441.192.042.122.132.362.121.97
EBITDA margin+7.6%+7.5%+10.0%+11.6%+11.2%+13.0%+10.3%+10.1%
Depreciation0.740.730.840.870.860.840.730.74
Interest0.160.120.130.140.130.150.130.13
Profit before tax0.920.391.741.421.931.551.441.63
Tax0.240.090.510.440.280.580.340.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue75.9475.1075.5675.3357.9268.6057.27
Revenue growth+1.1%-0.6%+0.3%+30.1%-15.6%+19.8%-
Other income1.961.071.091.720.940.880.85
Total expenses67.3068.0866.5466.7550.9459.0151.11
Employee cost17.4416.8414.5014.2412.509.809.30
EBITDA8.647.029.028.586.989.596.16
EBITDA margin+11.4%+9.4%+11.9%+11.4%+12.1%+14.0%+10.8%
Depreciation3.422.882.822.482.451.921.87
Interest0.540.550.380.360.450.640.82
Profit before tax6.644.666.917.465.027.914.32
Tax1.801.521.271.861.472.571.10
Net profit5.143.075.595.623.445.343.22
Net profit margin+6.8%+4.1%+7.4%+7.5%+5.9%+7.8%+5.6%
EPS (₹)40.2826.2147.1246.4929.6844.4826.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital1.201.201.201.201.201.201.20
Reserves & surplus56.8852.3749.6444.4339.1135.6930.78
Shareholders' funds (net worth)58.0853.5750.8445.6340.3136.8931.98
Secured loans4.221.673.072.942.724.583.43
Unsecured loans4.213.782.482.893.272.523.76
Total debt8.435.455.555.835.997.107.19
Total liabilities67.2259.4056.7051.4647.5445.2740.36
Assets
Gross block50.9948.3245.6843.9643.0441.1836.58
Net block23.8924.6424.0324.2625.8226.3623.66
Capital work in progress9.829.323.820.130.000.000.00
Investments0.010.010.010.010.010.010.01
Inventories7.127.216.216.906.785.165.51
Sundry debtors25.8525.7421.8521.3716.7422.5418.14
Cash & bank balances6.182.198.237.326.934.872.51
Loans & advances5.794.083.553.884.765.235.36
Total current assets44.9439.2239.8439.4735.2137.8031.52
Total current liabilities10.2913.429.9910.8012.6717.9714.20
Net working capital34.6525.8029.8528.6722.5419.8317.32
Total assets67.2259.4056.7051.4647.5445.2740.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.198.237.326.934.872.511.48
Net cash from operating activities4.244.868.232.455.198.215.49
Net cash from investing activities(3.17)(9.04)(6.27)(1.06)(1.89)(4.62)(1.14)
Net cash from financing activities2.91(1.85)(1.04)(1.01)(1.23)(1.24)(3.33)
Net change in cash3.99(6.03)0.910.382.072.361.02
Closing cash6.182.198.237.326.934.872.51
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.1%-0.6%+0.3%+30.1%-15.6%+19.8%-
EBITDA growth+23.1%-22.2%+5.1%+22.9%-27.2%+55.7%-
PBT growth+42.5%-32.6%-7.4%+48.6%-36.5%+83.1%+6.9%
Net income growth+67.4%-45.1%-0.5%+63.4%-35.6%+65.8%-
Revenue CAGR (3Y)+0.3%+9.0%+3.3%+9.6%+1.4%+9.8%+6.1%
EBITDA CAGR (3Y)+0.2%+0.2%-2.0%+11.7%+6.9%+29.7%-2.9%
Profitability & leverage
Net income margin+6.4%+4.2%+7.5%+7.4%+6.1%+7.8%+5.6%
Return on capital employed+11.3%+9.0%+13.5%+15.8%+11.8%+20.0%+12.9%
Return on net worth+8.7%+6.0%+11.7%+13.0%+9.2%+15.5%+10.6%
Debt / equity0.120.110.120.140.170.210.27
Long-term debt / equity0.100.060.060.060.120.180.22
Interest cover10.3413.296.135.909.938.3419.11
Efficiency & per share
Fixed asset turnover1.531.601.691.731.381.761.59
Inventory turnover10.6011.1911.5311.019.7012.869.32
Debtors turnover2.943.163.503.952.953.373.06
EPS (₹)40.2826.2147.1246.4929.6844.4826.90
Dividend per share (₹)3.503.503.503.503.503.502.00
Book value per share (₹)483.97446.41423.65380.24335.89307.45266.48

To see the full year-wise statements and ratios of Mercury Laboratories Limited, buy the company report.

Board of directors of Mercury Laboratories Limited

Mercury Laboratories has 6 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Rajendrakumar Ramanlal ShahManaging Director16 Feb 198244 Years 9 MonthsCurrent
Paresh Jagdishbhai MistryDirector01 Oct 20179 Years 1 MonthsCurrent
Dilip Ramanlal ShahDirector16 Feb 198244 Years 9 MonthsCurrent
Janki Rajendra ShahDirector05 Feb 20206 Years 9 MonthsCurrent
Sanjay PatelDirector14 May 20251 Years 6 MonthsCurrent
Jayantilal Dhaneshwar RavalDirector24 Jul 20242 Years 3 MonthsCurrent

Peer comparison

Mercury Laboratories Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Asence Pharma Private Limited₹77.56 Cr (FY 2025)19.0%Vadodara, Gujarat, India
Vasa Pharma Chem Pvt Ltd₹77.38 Cr (FY 2025)-8.0%Ahmedabad, Gujarat, India
Vapi Care Pharma Private Limited₹76.81 Cr (FY 2025)-11.0%Vapi, Valsad, Gujarat, India
Eskag Pharma Pvt Ltd₹76.72 Cr (FY 2024)0.0%Kolkata, West Bengal, India
Vovantis Laboratories Private Limited₹76.05 Cr (FY 2025)67.0%Vadodara, Gujarat, India
Higlance Laboratories Private Limited₹75.98 Cr (FY 2025)7.0%New Delhi, Delhi, India
Vital Therapeutics and Formulations Private Limited₹75.96 Cr (FY 2024)2.0%Hyderabad, Telangana, India
Mercury Laboratories Limitedthis company₹75.94 Cr (FY 2026)₹5.14 Cr6.8%1.1%492Mumbai, Maharashtra, India
Bennet Pharmaceuticals Limited₹75.82 Cr (FY 2025)11.0%Vadodara, Gujarat, India

To see the full peer comparison of Mercury Laboratories Limited, buy the company report.

Auditor

Mercury Laboratories Limited is audited by NARESH AND CO for the financial year 2025.

Auditor firmFinancial yearFirm registration number
NARESH AND COFY 2025106928W

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 73.70%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 26.30%.

Promoters: 73.70%Retail & Others: 26.30%
Mar 2026
QUARTER
73.70% Promoters
26.30% Retail & Others
Promoter holding - history
Now 73.70% · Mar 2026High 73.70% · Jun 2025Low 73.70% · Jun 2025
72%72.8%73.5%74.3%75%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 73.70%Sep 2025: 73.70%Dec 2025: 73.70%Mar 2026: 73.70%73.70%73.70%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters73.70%73.70%73.70%73.70%
Public26.30%26.30%26.30%26.30%

Charges & borrowings

Open charges
₹35.71 Cr
Satisfied charges
₹33.61 Cr
Breakdown by lending institutions
Sidbi₹19.90 Cr
Hdfc Bank Limited₹15.81 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
06 Mar 2026101257925Sidbi₹18 CrOpen
19 Dec 2024101022958Sidbi₹1.9 CrOpen
14 Mar 2024100886860Hdfc Bank Limited₹20 LakhOpen
25 May 2023100723959Hdfc Bank Limited₹50 LakhOpen
27 Sep 2021100500033Hdfc Bank Limited₹7.06 CrOpen

To see the full charge records of Mercury Laboratories Limited, buy the company report.

Total charge records: 19 View all charges

Deals & funding

Mercury Laboratories Limited has 1 deal on record (1 market trade); the latest was in May 2023.

Total deals
1
Market trade
1

Deals on record (1 of 1)

WhenDealAmountParties
May 2023Market trade₹1.55 CrBuyer: an individual
Seller: an individual

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Mercury Laboratories Limited has 5 MSME Form 1 returns on record between 2019 and 2021, listing 616 overdue payments to 33 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 33)

SupplierAmount dueDue sinceReported on
an individual supplier
an individual supplier
an individual supplier
an individual supplier
an individual supplier

To see the full MSME payment records of Mercury Laboratories Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Mercury Laboratories Limited has a workforce of 492 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
492
Active EPFO establishments
1
Employee growth
4%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27492
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17
FY 2015-16
FY 2014-15

To see the full employee and EPFO history of Mercury Laboratories Limited, buy the company report.

GST

Mercury Laboratories has 10 GST registrations: 8 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
10
Active
8
Cancelled / inactive
2
GSTINStateStatusRegistered on
27AAACM0414D2Z5MaharashtraActive14 Dec 2017
09AAACM0414D1Z4Uttar PradeshActive01 Jul 2017
24AAACM0414D1ZCGujaratActive01 Jul 2017
33AAACM0414D1ZDTamil NaduActive01 Jul 2017

To see the full GST registrations and return filing status of Mercury Laboratories Limited, buy the company report.

Recent activity

Mercury Laboratories Limited has 24 board changes on record since 1982: 15 appointments and 9 cessations. The latest: Bharat Dhirajlal Mehta ceased to be Director on 14 May 2025.

Filing
Mercury Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Sidbi amounted to Rs. 18.00 Cr with Charge ID 101257925 was registered on 06 Mar 2026.
Charges
A charge with Sidbi of Rs. 18.00 Cr registered on 06 Mar 2026 with Charge ID 101257925 was modified on 06 Mar 2026.
AGM
Mercury Laboratories Limited last Annual general meeting of members was held on 13 Aug 2025 as per latest MCA records.
Ceased
Bharat Dhirajlal Mehta ceased to be Director.
Appointed
Sanjay Patel was appointed as Director.
Charges
A charge with Sidbi amounted to Rs. 1.90 Cr with Charge ID 101022958 was registered on 19 Dec 2024.
Ceased
Divyakant Ramniklal Zaveri ceased to be Director.
Appointed
Jayantilal Dhaneshwar Raval was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.20 Cr with Charge ID 100886860 was registered on 14 Mar 2024.
Charges
A charge registered on 09 Nov 2020 via Charge ID 100389106 with Hdfc Bank Limited was fully satisfied on 07 Nov 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.50 Cr with Charge ID 100723959 was registered on 25 May 2023.

56 earlier events are in the company report.

Frequently asked questions

Mercury Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 February 1982 (44+ years old) and is registered under CIN L74239MH1982PLC026341. Listed on BSE: 538964.

Mercury Laboratories reported revenue of ₹75.94 Cr for FY 2025-26 (up 1.1% YoY) based on standalone financials.

Mercury Laboratories has 6 current directors:

The latest financial statements of Mercury Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 13 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Mercury Laboratories is 27AAACM0414D2Z5, registered in Maharashtra. The company has 10 GST registrations in all, of which 8 are active and 2 are cancelled or inactive. Other active GSTINs include 09AAACM0414D1Z4 (Uttar Pradesh), 24AAACM0414D1ZC (Gujarat), 33AAACM0414D1ZD (Tamil Nadu).

The CIN (Corporate Identification Number) of Mercury Laboratories is L74239MH1982PLC026341. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Mercury Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 538964).

Mercury Laboratories has 71 court cases on record: 40 filed by the company and 31 filed against it. 13 are pending. Most are in the district courts.

Mercury Laboratories was incorporated on 12 February 1982, making it 44+ years old. It is registered with the Registrar of Companies, Mumbai.

Mercury Laboratories has 1 deal on record (1 market trade); the latest was in May 2023.

The peers of Mercury Laboratories by revenue are Asence Pharma Private Limited, Vasa Pharma Chem Pvt Ltd, Vapi Care Pharma Private Limited, Eskag Pharma Pvt Ltd, Vovantis Laboratories Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Bharat Dhirajlal Mehta ceased to be Director on 14 May 2025. Sanjay Patel was appointed as Director on 14 May 2025. Divyakant Ramniklal Zaveri ceased to be Director on 25 Jul 2024. Mercury Laboratories has 24 board changes on record in total.